Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

chimmitecan

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Aim:To investigate the pharmacokinetics and disposition of simmitecan (L-P) that was a water-soluble ester prodrug of chimmitecan… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2012
2012
Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs 
  • figure 1
2011
2011
Simmitecan (L-P) is an anticancer ester prodrug, which involves activation to chimmitecan (L-2-Z). In the current study, a liquid… Expand
  • figure 2
  • figure 3
  • figure 5
  • figure 6
  • table 1
2010
2010
The invention provides a method for determining the content of simimtecan and chimmitecan in human or animal whole blood. The… Expand
Highly Cited
2008
Highly Cited
2008
Camptothecins (CPT) activate S or G2-M arrest and the homologous recombination (HR) repair pathway in tumor cells. In this… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2007
Highly Cited
2007
Purpose: This study aimed to evaluate antitumor activities and pharmacologic profiles of chimmitecan, a novel 9-small-alkyl… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
  • figure 3
2006
2006
Proc Amer Assoc Cancer Res, Volume 47, 2006 5529 Recently, lipophilic analogs of camptothecin are found to overcome the… Expand